Previous Close | 0.0150 |
Open | 0.0150 |
Bid | 0.0100 x N/A |
Ask | 0.0150 x N/A |
Day's Range | 0.0150 - 0.0150 |
52 Week Range | 0.0050 - 0.0500 |
Volume | |
Avg. Volume | 28,079 |
Market Cap | 948,750 |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0500 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
New York, New York--(Newsfile Corp. - March 31, 2023) - Plantable Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") is pleased to announce the appointment of Michael Townsend, Geoff Balderson, Arndt Roehlig and Kevan Matheson as directors of the Company in replacement of Elisa Udaskin, Jason Campagna, Peter Hughes and Nadja Pinnavaia who have resigned as directors of the Company effective today. The Company also announces the appointment of Zayn Kalyan, Geoff ...
New York, New York--(Newsfile Corp. - March 13, 2023) - Plantable® Health Inc. (NEO: PLBL) (OTC Pink: PLBLF) ("Plantable" or the "Company") is pleased to announce the appointment of Mr. Zayn Kalyan to the Company's Board of Directors, in replacement of Mr. David Kopp, who has resigned.Mr. Kalyan is an experienced investment banker and business development executive. Starting his career as a software engineer, his background in the "ground-up" development of startup technology companies ...
New York, New York--(Newsfile Corp. - January 24, 2023) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today announced that the Board of Directors of the Company (the "Board"), with the support of management, has begun a comprehensive review of the Company's strategic alternatives.The Board is currently exploring various strategic alternatives, including but not limited to, a potential sale of the Company and/or its assets, and/or commencing an orderly process
New York, New York--(Newsfile Corp. - January 5, 2023) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today provides an update on its distribution partnership with CookUnity, a chef-to-eater marketplace, which commenced last month."Our partnership with CookUnity is off to a strong start, with customer demand outstripping initial projected volumes. As a result, we have been asked by CookUnity to significantly increase production to meet their demand. These new
New York, New York--(Newsfile Corp. - December 8, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company"), today announces it has been selected to be the meal production and delivery partner for Pivio Health ("Pivio"), a lifestyle medicine program owned by the Lifestyle Medicine Institute (LMI). This new agreement further extends Plantable's B2B network across the United States."Our partnership with Pivio is an exciting milestone, as it not only expands ...
New York, New York--(Newsfile Corp. - November 10, 2022) - Plantable Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company"), provides a clinically proven dietary intervention program to reverse and prevent chronic disease, today reported the financial results for the third quarter ended September 30, 2022. "Food as Medicine is now here. The recent White House announcement of their support of insurance coverage for dietary lifestyle interventions, including Food as Medicine, paves
New York, New York--(Newsfile Corp. - October 25, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today announces it has entered into a new distribution agreement with CookUnity, a Brooklyn-based chef-to-eater marketplace, to distribute Plantable's fresh meals across the East Coast, with future expansion to the rest of the United States. This agreement represents a significant milestone for Plantable. CookUnity is the first chef-to-eater meal subscription
New York, New York--(Newsfile Corp. - October 18, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today announces the opening of a new Clinical Trial, NUTRIVENTION-3, at Memorial Sloan Kettering Cancer Center (MSK) in New York, New York with Dr. Urvi Shah as Principal Investigator. This trial follows on the back of the promising recently presented preliminary results for NUTRIVENTION study (NCT04920084). The primary objective for this trial is ...
New York, New York--(Newsfile Corp. - October 7, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company"), today announces the launch of The Road Athlete Challenge, fueled by Plantable ("The Challenge"), which is a dietary intervention program aimed to improve the health of U.S. truck drivers. The Challenge is in collaboration with Road Dog Radio's, Tim Ridley Show. The US Census states that there are more than 3.5 million truck ...
New York, New York--(Newsfile Corp. - October 4, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today announces preliminary results from its Myeloma Cancer Trial, NUTRIVENTION clinical trial (NCT04920084), that were presented at the 19th International Myeloma Society Annual Meeting, showing the Company as a potential intervention in empowering patients with diet-related chronic conditions."We're very pleased to share these preliminary results. Nearly hal
New York, New York--(Newsfile Corp. - September 29, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") announced its plans to expand the Company's reach into the self-funded marketplace with the launch of the RebootRx. Proven on the individual level, Plantable's RebootRx product will offer self-funded employers a value-based solution to reverse chronic disease with high levels of adherence and engagement, leading to better outcomes both for the individual's
New York, New York--(Newsfile Corp. - August 9, 2022) - Plantable Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company"), a clinically supported dietary intervention program to reverse and prevent chronic disease, today reported the Company's financial results for the second quarter ended June 30, 2022."When we founded Plantable, the concept of having a turnkey solution that reversed diet-related chronic disease, paid for by the insurer, was novel. We were very early," said ...
New York, New York--(Newsfile Corp. - July 19, 2022) - Plantable® Health Inc. (NEO: PLBL) (OTCQB: PLBLF) ("Plantable" or the "Company") today announces that its Prostate Cancer Trial at Weill Cornell Medicine, NewYork-Presbyterian and at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center ("John Hopkins") has commenced enrollment. This multi-center randomized control trial led by David M. Nanus, MD., a medical oncologist and clinical investigator at Weill Cornell Medicine, NewYork-Presbyteri